Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Dr., Baltimore, MD, USA.
RTI International, Research Triangle Park, 3040 East Cornwallis Rd., NC, USA.
J Anal Toxicol. 2020 Jan 7;44(1):1-14. doi: 10.1093/jat/bkz038.
As cannabis has become more accessible, use of alternative methods for cannabis administration such as vaporizers has become more prevalent. Most prior controlled pharmacokinetic evaluations have examined smoked cannabis in frequent (often daily) cannabis users. This study characterized the urinary excretion profile of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH), the primary analytical outcome for detection of cannabis use, among infrequent cannabis users following controlled administration of both smoked and vaporized cannabis. Healthy adults (N = 17), with a mean of 398 (range 30-1,825) days since last cannabis use, smoked and vaporized cannabis containing 0, 10, and 25 mg of Δ9-tetrahydrocannabinol (THC) across six outpatient sessions. Urinary concentrations of THCCOOH were measured at baseline and for 8 h after cannabis administration. Sensitivity, specificity, and agreement between three immunoassays (IA) for THCCOOH (with cutoffs of 20, 50, and 100 ng/mL) and gas chromatography-mass spectrometry (GC/MS) results (confirmatory concentration of 15 ng/mL) were assessed. THCCOOH concentrations peaked 4-6 h after cannabis administration. Median maximum concentrations (Cmax) for THCCOOH were qualitatively higher after administration of vaporized cannabis compared to equal doses of smoked cannabis. Urine THCCOOH concentrations were substantially lower in this study relative to prior examinations of experienced cannabis users. The highest agreement between IA and GC/MS was observed at the 50 ng/mL IA cutoff while sensitivity and specificity were highest at the 20 and 100 ng/mL IA cutoffs, respectively. Using federal workplace drug-testing criteria (IA cutoff of 50 ng/mL and GC/MS concentration ≥15 ng/mL) urine specimens tested positive in 47% of vaporized sessions and 21% of smoked sessions with active THC doses (N = 68). Urinary concentrations of THCCOOH are dissimilar after administration of smoked and vaporized cannabis, with qualitatively higher concentrations observed after vaporization. Infrequent users of cannabis may excrete relatively low concentrations of THCCOOH following acute inhalation of smoked or vaporized cannabis.
随着大麻的使用变得更加便捷,替代吸食方法,如汽化器,也变得越来越流行。大多数之前的受控药代动力学评估都检查了经常(通常是每天)吸食大麻的人吸食的大麻。本研究描述了 11-去甲-9-羧基-Δ9-四氢大麻酚(THCCOOH)的尿排泄特征,这是检测大麻使用的主要分析结果,在最近一次使用大麻 398 天(范围 30-1825 天)后,对吸食者进行了受控的烟雾和汽化大麻管理。健康成年人(N=17),最近一次使用大麻的时间为 398 天(范围 30-1825 天),在六个门诊期间分别吸食了含有 0、10 和 25 毫克 Δ9-四氢大麻酚(THC)的烟雾和汽化大麻。在大麻给药前后 8 小时测量尿中 THCCOOH 的浓度。评估了三种免疫分析(IA)检测 THCCOOH(检测限分别为 20、50 和 100ng/ml)与气相色谱-质谱联用(GC/MS)结果(确证浓度为 15ng/ml)之间的灵敏度、特异性和一致性。THCCOOH 浓度在大麻给药后 4-6 小时达到峰值。与相等剂量的吸烟大麻相比,汽化大麻给药后 THCCOOH 的中位最大浓度(Cmax)定性更高。与以前对经验丰富的大麻使用者的检查相比,本研究中的尿 THCCOOH 浓度要低得多。IA 和 GC/MS 之间的最高一致性是在 50ng/mlIA 截点观察到的,而灵敏度和特异性分别在 20 和 100ng/mlIA 截点最高。使用联邦工作场所药物检测标准(IA 截点为 50ng/ml 和 GC/MS 浓度≥15ng/ml),68 个有活性 THC 剂量的汽化(47%)和吸烟(21%)样本的尿液标本呈阳性。吸烟和汽化大麻给药后,尿中 THCCOOH 的浓度不同,汽化后观察到的浓度定性更高。吸食大麻的不频繁使用者在急性吸入烟雾或汽化大麻后,可能会排出相对较低浓度的 THCCOOH。